Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice

INTRODUCTION: Current therapy for Alzheimer's disease (AD) focuses on delaying progression, illustrating the need for more effective therapeutic targets. Histone deacetylase 6 (HDAC6) modulates tubulin acetylation and has been implicated as an attractive target. HDAC6 is also elevated in postmo...

Descripción completa

Detalles Bibliográficos
Autores principales: Majid, Tabassum, Griffin, Deric, Criss, Zachary, Jarpe, Matthew, Pautler, Robia G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975056/
https://www.ncbi.nlm.nih.gov/pubmed/29854936
http://dx.doi.org/10.1016/j.trci.2015.08.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975056/
https://www.ncbi.nlm.nih.gov/pubmed/29854936
http://dx.doi.org/10.1016/j.trci.2015.08.001

Ejemplares similares